An investigation into closed-loop treatment of neurological disorders based on sensing mitochondrial dysfunction by Adams, Scott D. et al.
 DRO  
Deakin Research Online, 
Deakin University’s Research Repository  Deakin University CRICOS Provider Code: 00113B 
An investigation into closed-loop treatment of neurological disorders based on 
sensing mitochondrial dysfunction 
Citation:  
Adams, Scott D., Kouzani, Abbas, Tye, Susannah J., Bennet, Kevin E. and Berk, Michael 2018, An 
investigation into closed-loop treatment of neurological disorders based on sensing 
mitochondrial dysfunction, Journal of neuroengineering and rehabilitation, vol. 15, Article 







© 2018, The Authors 






Downloaded from DRO:  
http://hdl.handle.net/10536/DRO/DU:30108838 
REVIEW Open Access
An investigation into closed-loop treatment
of neurological disorders based on sensing
mitochondrial dysfunction
Scott D. Adams1, Abbas Z. Kouzani1* , Susannah J. Tye2, Kevin E. Bennet3 and Michael Berk4
Abstract
Dynamic feedback based closed-loop medical devices offer a number of advantages for treatment of heterogeneous
neurological conditions. Closed-loop devices integrate a level of neurobiological feedback, which allows for real-time
adjustments to be made with the overarching aim of improving treatment efficacy and minimizing risks for adverse
events. One target which has not been extensively explored as a potential feedback component in closed-loop
therapies is mitochondrial function. Several neurodegenerative and psychiatric disorders including Parkinson’s
disease, Major Depressive disorder and Bipolar disorder have been linked to perturbations in the mitochondrial
respiratory chain. This paper investigates the potential to monitor this mitochondrial function as a method of
feedback for closed-loop neuromodulation treatments. A generic model of the closed-loop treatment is developed to
describe the high-level functions of any system designed to control neural function based on mitochondrial response to
stimulation, simplifying comparison and future meta-analysis. This model has four key functional components including:
a sensor, signal manipulator, controller and effector. Each of these components are described and several potential
technologies for each are investigated. While some of these candidate technologies are quite mature, there are still
technological gaps remaining. The field of closed-loop medical devices is rapidly evolving, and whilst there is a lot of
interest in this area, widespread adoption has not yet been achieved due to several remaining technological hurdles.
However, the significant therapeutic benefits offered by this technology mean that this will be an active area for
research for years to come.
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Background
Neurological conditions are a significant global health
issue, with the World Health Organization (WHO)
estimating that over a billion people worldwide are
effected [1]. These conditions can range from neurode-
generative diseases such as Alzheimer’s and Parkinson’s
disease, to depression which is ranked as the single
largest contributor to global disability (7.5% of all years
lived with disability in 2015) [2]. There are a number of
treatments available for these conditions with varying
degrees of effectiveness, with medication and psycho-
therapy playing a key role as front line treatments.
Unfortunately, these disorders are heterogeneous, with a
lack of effective precision medicine approaches available
to target the individualized pathophysiological mecha-
nisms contributing to disease processes in any single
patient, and consequent difficulty in optimizing their
response to specific treatments [3, 4]. In particular, a
predictable subset of patients experience complications
and/or unresponsiveness to traditional treatments, even
when using a combined approach with multiple inter-
ventions [5, 6]. This has led to a number of researchers
investigating “closed-loop” solutions, these solutions inte-
grate feedback on the effectiveness of the treatment allow-
ing it to be modified “on the fly” according to each
individual’s requirements [7]. However, the most appropri-
ate targets for the feedback are still a matter of debate.
Mitochondria may play a pivotal role in several neuro-
logical disorders and may be a useful proof of concept
target for a closed-loop neurological control system. [8–10].
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This is not a surprise as the mitochondrion is a fundamen-
tal component of a number of crucial functions within the
human body and critical for healthy brain function. A large
body of evidence suggests that a disruption in normal
mitochondrial function can lead to significant dysfunction
in higher organisms [11]. As the brain is the most energy
demanding tissue, using 20% of the body’s total energy,
mitochondrial dysfunction is invariably expressed in the
brain. This review explores the link between neurological
conditions and mitochondrial dysfunction, and posits a
generic interventional model for a closed-loop control
system based on this link. In addition, this review explores
several potential candidate technologies for the functional
components identified in the generic model, which could
be used to achieve the overall goal of a closed-loop system
to treat neurological and psychiatric disorders using mito-
chondrial function as a biomarker.
Mitochondria
Mitochondria are energy producing organelles found in
large numbers in eukaryotic cells, comprised of four
primary sections: an outer membrane, an intermem-
brane space, an inner membrane, and an inner matrix.
Biochemical and biology studies describe mitochondria
as the “powerhouse of the cell” [12]. This description is
used because in most eukaryotes the common energy
carrier Adenosine 5′-triphospate (ATP) is phosphory-
lated from ADP in the mitochondria. This mitochondrial
respiration is achieved through oxidative phosphoryl-
ation, where a phosphate group is introduced into ADP
to form ATP [13].
ADPþ Pi þ free energy⇌ATPþH20
This process is made possible by a proton gradient
across the inner mitochondrial membrane, which
describes the movement of positively charged hydrogen
ions. This movement of H+ generates a pH gradient and
an electric field (Δψm) across the inner membrane,
which adds the required energy to enable the energetic-
ally unfavorable reaction between ADP and Pi, thus
producing ATP [14]. The details about this reaction were
outlined in a seminal work by Peter Mitchell [15], which
was recognized by a Nobel Prize in 1978.
ATP is a compound found in all living organisms, and
serves as the primary “energy currency” of the cell. An
ATP molecule consists of ribose, adenine, and a string of
three phosphate groups, which are added or removed to
transfer energy, shuttling between the triphosphate ATP,
biphosphate ADP and monophosphate AMP forms, each
with serially lower energy potential. Due to ATP’s high
phosphate-transfer potential, it is utilized through oxida-
tion and reduction reactions in a number of crucial
biological processes including: membrane transport,
cellular mitosis and muscular contraction [12]. Further-
more, ATP is a critical component in both intercellular
and extracellular signaling, and acts as either a co-
transmitter, or the sole transmitter in the majority of
nerves in the central and peripheral nervous systems
[16, 17]. Mitochondrial ATP production is an intrinsic
component in a number of critical mechanisms within
the human body. Hence, any disruption to this produc-
tion can lead to a disturbance of many disparate func-
tions such as cellular mitosis, muscular contraction, and
neurotransmission.
In addition to ATP production, research findings indicate
that mitochondria perform functions including, but not
limited to the regulation of: cell apoptosis, calcium hand-
ling, free radical generation and reactive oxygen species
(ROS) production [18–21]. Cellular apoptosis is a signaling
cascade which leads to the death of a cell, which occurs
when cells are subject to intracellular damage or physio-
logical cues, and is commonly regulated by a subset of
intracellular proteases called caspases [18, 21–23]. Mito-
chondria control the activation of these caspases through
mitochondrial outer membrane permeabilization (MOMP),
which utilizes the Bcl-2 family of proteins to regulate apop-
tosis [23, 24]. Calcium handling in mitochondria has been a
topic of investigation since the 1960s [25]. Current evidence
suggests that calcium levels within the mitochondria not
only play critical intracellular signaling roles, but assist in
determining thresholds for cellular death, and play an
essential role in fine-tuning cellular energetics [26, 27].
However, even after more than five decades of investigation,
there still remain a number of significant open questions in
this domain, particularly in the specific physiological roles
of mitochondrial calcium handling [27]. The multifaceted
role of mitochondria suggests that even subtle dysfunction
could have far-reaching consequences.
Linking mitochondrial dysfunction and
neurological disorders
The links between mitochondrial dysfunction and neuro-
logical disorders have been an active area of investigation.
Tissue in areas with high energy demands, such as the
brain, heart and endocrine system is highly reliant on mito-
chondrial based aerobic respiration [28]. The brain is highly
dependent on a continuous and efficient energy supply and
is consequently considerably vulnerable to mitochondrial
perturbation. Evidence suggests that this perturbation may
significantly impact neural viability, neural plasticity and
long-term cellular resilience, which are linked to the patho-
genesis and pathophysiology of several neurological and
psychiatric disorders [29–34]. This paper examines some
most common conditions including Parkinson’s disease,
Alzheimer’s disease and bipolar disorder and explores their
links to mitochondrial dysfunction.
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Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive neurodegenerative
disease first described in the early 1900s by Alois Alzheimer
which is estimated to affect 6% of the population over 65,
with the incidence rate increasing exponentially with age
[35–37]. AD is characterized by progressive decline of
cognitive function usually beginning with difficulties with
recent memory but eventually affecting all intellectual func-
tions [38]. The majority of AD cases are sporadic, for which
the causal factors are still unknown [39]. The prevalent
model of AD (the Amyloid Cascade model) propounds that
AD pathogenesis is linked to the overproduction of the
beta-amyloid (Aβ) peptide in neurons, however, the exact
cause of this overproduction is disputed [40, 41].
In 2004, Swerdlow RH and Khan SM [42] posited a
“mitochondrial cascade hypothesis” as a specific cause of
sporadic late-onset AD. This hypothesis provides a unifying
framework for AD pathology, citing low rates of oxidative
phosphorylation, and high rates of ROS production as a key
cause for sporadic, late-onset AD [42–44]. This hypothesis
explains one of the key characteristics of AD, which is the
correlation of incidence with increasing age. There is a
significant amount of evidence suggesting that over time,
mitochondrial DNA accumulates an increasing number of
mutations resulting in a marked decrease of ATP produc-
tion, concurrent with increased ROS generation [45–48]. A
number of researchers have identified this mitochondrial
dysfunction as a potential pathway for developing more
efficacious intervention strategies [41, 49]. However, this
link between AD, mitochondrial dysfunction and Aβ over-
production is an area of intense current research, and the
development of effective tools and techniques to aid in this
research is of considerable importance [41, 50–54].
Parkinson’s disease
Parkinson’s disease (PD) is the second most common neu-
rodegenerative condition after Alzheimer’s disease, charac-
terized by progressively increasing resting tremor, rigidity,
bradykinesia, and postural instability [55–57]. The connec-
tion between this disorder and mitochondrial dysfunction
has been investigated since the early 1980s, when a number
of drug users developed parkinsonism after mistakenly
administering a synthetic drug which inhibited complex I,
an enzyme crucial to the mitochondrial respiratory chain
[58, 59]. Since this time, a compelling amount of evidence
has been discovered indicating that PD is associated with
mitochondrial dysfunction, and has identified this dysfunc-
tion as a potential pathway for intervention [60–66].
Mitochondrial dysfunction in this case can be expressed as
a decrease in ATP production and an increase in ROS
generation [59, 64, 65, 67]. One of the difficulties in study-
ing mitochondrial response is the specificity required of the
assaying technique. A study by Schapira AH, Cooper JM,
Dexter D, et al. [68] found that in postmortem examination,
PD tissues exhibited a 30–40% inhibition of Complex I
activity. However, Davey GP and Clark JB [69] found in a
whole brain assay that Complex I activity could be reduced
by ~ 72% before significant changes in mitochondrial
respiration took place [59, 67]. Not until a further study,
specifically investigating synaptic mitochondria, was found
that as little as a ~ 25% reduction in Complex I severely
inhibited ATP production [70]. This clearly demonstrates
the need for high accuracy measurement techniques to be
able to detect potential dysfunction, which may only be
present in a specific region, particular to that disorder.
There is a great deal of complexity in studying a disorder
with a heterogeneous pathogenesis and pathophysiology,
and further research is still required to develop a more
complete understanding of the mitochondrial link in PD.
Amyotrophic lateral sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease
is a fatal neurological disease with a life expectancy of ap-
proximately 3 years after onset [71]. The pathogenesis of
ALS is still not fully understood which significantly limits
the treatment options available [72]. Some of the mecha-
nisms which have shown links to the condition include oxi-
dative stress, protein misfolding and endoplasmic reticulum
stress, which are intrinsically connected to mitochondrial
dysfunction [73–77]. As with PD and AD, it has been
suggested that ALS shares a link with significant disruption
to the mitochondrial respiratory chain and a decrease in
ATP production and an increase in ROS generation, hence,
addressing this through antioxidants and mitochondrial
modulators has been a target for a number of treatments
[72, 78–81]. Unfortunately, as seen in a meta-analysis by
Benatar M [82], these techniques have had difficulties
transitioning from the lab to a clinical outcome. Cozzolino
M and Carrì MT [72] suggested that the investigated treat-
ments may be too narrow to show clinical significance, and
that more complex treatment options directed at multiple
therapeutic targets should be investigated.
Major depression and bipolar disorder
Depressive disorders are a significant cause of disability
globally, and have consistently been among the leading
causes of burden in the Global Burden of Disease (GBD)
studies [83, 84]. The exact pathophysiology of unipolar
depressive disorders such as major depressive disorder
(MDD) is not comprehensively understood, and depres-
sion lacks a specific reproducible biomarker [85, 86].
This in part is likely due to the heterogeneous nature of
the illness. New theories have been proposed in light of
recent research demonstrating several biological factors
contributing to the pathophysiology of depression and
other mood disorders [86–88]. One of the first large
scale studies to show a relationship between genetic
abnormalities and MDD was a study by the CONVERGE
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consortium [88] on more than 10,000 subjects with
recurrent MDD. This study identified two loci which
contribute to the risk for MDD, including the SIRT1
gene which protects against oxidative stress through
regulating mitochondrial function. In addition, several
studies on the co-morbidity of mitochondrial disorders
and MDD have shown that individuals with abnormal
cerebral energy metabolism (ATP production) have a
much higher incidence rate of MDD and bipolar
disorder than the general population [10, 89–91]. This
does not, however, provide a generalized pathogenesis
for MDD, as the disorder has a highly complex psychi-
atric phenotype without a unitary pathogenesis or patho-
physiology [85]. What this does elucidate, however, is
that investigation into treatments in this area could po-
tentially be valuable for elucidating critical operative
pathways, which may translate into benefits for sufferers,
potentially including the subset of patients who are
resistant to traditional anti-depressant intervention [87].
In comparison, the links between bipolar disorder (BPD)
and mitochondrial dysfunction are much clearer, with a
growing body of evidence indicating that mitochondrial
respiratory chain perturbations are closely linked to the
pathogenesis and progression of the disorder [8, 34, 92–95].
BPD is a biphasic disorder where patients exhibit distinct
manic and depressive stages. A growing body of evidence is
beginning to associate the mania phase of the disorder with
an increase in cerebral energy generation (ATP production)
and resting energy expenditure, whereas depression is asso-
ciated with the inverse [96–98].
A recent review of the literature by Morris G, Walder K,
McGee SL, et al. [97] presents a model of BPD which
brings together the results of many separate studies, and
expounds upon links implicating state dependent mito-
chondrial dysfunction in the biphasic pathophysiology of
BPD. Several studies have found that parameters directly
linked to ATP production, including uric acid and intracel-
lular calcium, are increased in patients experiencing the
manic phase of the disorder, and decreased in patients
experiencing depression, these changes can alter week to
week [8, 99–101]. This shows the potential of mitochon-
drial dysfunction for more than just a long-term indicator
of progression, but as a dynamic biomarker which may
provide information on dynamically changing symptoms.
A common intervention for BPD is mood stabilizing
drugs such as lithium and valproate, which have effects
on both the manic and depressive stages of the disorder.
The work of Cui J, Shao L, Young LT, et al. [102] has
shown that these agents also have multiple actions on
mitochondrial biogenesis. Results from the Systematic
Treatment Enhancement Program for Bipolar Disorder
(STEP-BD) study in the USA found that 40% of patients
with bipolar disorder used 3+ medications and 18% used
4 or more, driven by suboptimal outcomes with first line
therapies [103]. The high prevalence of utilization of
complex drug regimens illuminates one of the key issues
in managing a multi-phase disorder such as BPD. If a
treatment option was available which could detect the
pathophysiology underpinning the current phase of the
disorder and applied an appropriate intervention, this
could greatly increase the efficacy of BPD treatment.
Generic model
In response to the issues outlined in Section III, the authors
propose a generic model of an in-vivo closed-loop, feedback
based control system for neurological conditions, based on
mitochondrial function, shown in Fig. 1. This model aims
to describe the high-level functions of a system designed to
control neurological conditions, grounded on feedback-
based modulation of mitochondrial function, simplifying
comparison and enabling future meta-analysis. Open-loop
treatment options provide the same intervention to the
patient irrespective of system status or response. A closed-
loop system through the inclusion of a feedback compo-
nent enables the system to dynamically react to the biologic
effect and the subsequent treatment needs of a patient.
The key components of a system aiming to control these
conditions in-vivo are the sensor, signal manipulator
controller, and the effector. The sensor component allows
for the current mitochondrial function of the subject to be
measured, this may be a direct measurement or an indirect
measurement, and communicated to the control system.
The sensing component comprises of a single transducer
or multiple transducers; these transducers can vary in loca-
tion as well as type. The signal manipulator element
receives the signal from the sensor and alters it such that it
can be read by the control system. The controller compo-
nent receives the output from the signal manipulation
Fig. 1 Generic model of a mitochondrial dysfunction based control system
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element and estimates the mitochondrial function. Once
this is complete, the controller runs through a predeter-
mined control algorithm and determines what signal to
send to the effector. The effector is used to alter the condi-
tions within the in-vivo tissue. The effector component
comprises one or more methods which can be instigated in
a controllable manner.
Sensor
The key aim of the sensing component is to accurately
quantify mitochondrial function or a related function in-
vivo and pass this measurement to the control system.
Through the investigation carried out in Section III, it
was observed that all the examined disorders expressed
some common features during mitochondrial dysfunc-
tion: abnormalities in intracellular calcium regulation,
altered ATP production, and increased oxidative stress
leading to apoptosis (programmed cell death). ATP
levels in the extracellular matrix have been closely linked
to mitochondrial dysfunction based apoptosis, as well as
intracellular calcium regulation [104–108]. The mechanism
of purinergic receptor activation (particularly P2X7R) by
extracellular ATP has been recognized as a danger signal
within the brain. This is linked directly to alterations in
intracellular calcium levels and mitochondrial function, and
can significantly alter the mitochondrial membrane
potential [105, 107–110]. During the activation of these
receptors, the concentration of extracellular ATP can
increase 106 from the background of ~ 10 nM, up to
1 mM [104, 111].
In order for any ATP sensing mechanism to be effective
in this context, it must be selective, sensitive, stable, and
fast to respond. Additionally, the sensing technique must
also be suitable for long term in-vivo use in unconstrained
subjects. Ideally this technique would be non-invasive,
however the great difficulty in accurately sensing neuro-
logical function in real-time, means that the accuracy of
such a technique is significantly reduced. There are a num-
ber of neurological targets which show clear potential for
sensing mitochondrial dysfunction in this manner, however,
these would be selected depending on the disorder. The
substantia nigra (a nucleus in the midbrain) and the cholin-
ergic nucleus basalis, are an obvious target for PD as a
number of studies have linked mitochondrial dysfunction
in these regions with the disorder, while for AD the locus
coeruleus may be a more effective target, in mood disorders
the changes appear to be more global [67, 68, 112].
Several techniques are available which can be used to
sense extracellular ATP function in-vivo. They use a variety
of transduction mechanisms to convert the ATP concentra-
tion to a measurable quantity. One of the earliest studies
describing a method of quantifying ATP concentration was
published by Kerr SE and Daoud L [113] in 1935. This study
detected the number of phosphates in a molecule in 24
species of animal by measuring the quantity of hydrolyzable
phosphorus. However, a 1947 discovery by William McElroy
uncovered that ground fireflies emitted a flash of light when
combined with ATP [114]. This occurs because firefly lucif-
erin when combined with ATP and magnesium produces
luciferase with an intensity directly related to the ATP
concentration within the sample [115]. The discovery of a
method which reliably and accurately allows for the calcula-
tion of ATP within a sample opened up a new era of chemi-
luminescent assaying for quantifying ATP concentrations.
Adams S, Kouzani AZ, Bennet K, et al. [116] found
that modern chemiluminescent ATP transduction tech-
niques were highly accurate and were able to retrieve
results rapidly. Many research studies have successfully
used these techniques to measure the concentration of
ATP in-vivo, however, all the works reviewed as part of
this study required the subject to be stationary, and
gathered results using highly sophisticated imaging equip-
ment which is resistant to miniaturization [117–122].
Traditional chemiluminescent techniques require analysis
through vision recognition techniques which is computa-
tionally intensive, and requires a powerful control system
to be effective [123]. More modern techniques utilize
optical fibers in order to gather assays in a more selective
manner, allowing for a higher special resolution; however,
these optic fibers often have diameters in the hundreds of
microns and require complex readers in order to gather
results [124]. In addition to these disadvantages, much of
the surveyed research which used chemiluminescent tech-
niques to measure cerebral ATP was performed on post-
mortem subjects or on in-vitro cell cultures [125–127].
In order to address some of the drawbacks found in
chemiluminescent sensor systems, a number of researchers
have been investigating electrochemical techniques such as
amperometric biosensing as an alternative. Constant poten-
tial amperometry consists of the application of a fixed
potential between a working electrode and a reference elec-
trode, while measuring the resultant current. The current is
a result of oxidation or reduction of analytes on the surface
of the working electrode, and is proportional to the concen-
tration of the analyte in the media [128]. This technique
allows for measurements to be taken with high spatial
and temporal resolution, while remaining suitable for
miniaturization [129, 130]. When using unmodified
electrodes, this technique often does not achieve a high
degree of selectivity, so films or enzymes are added to
the electrodes to increase the electrochemical response
of the analyte of interest, on the working electrode
surface [130]. Amperometric biosensors are electrodes
which are integrated with biological recognition layers
to allow for a large variety of analytes to be measured
(including ATP) with a high degree of sensitivity and
selectivity [131]. This type of sensor is suitable for
miniaturization, and can even perform measurements
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while being carried by the subject during normal
activity [132].
As can be seen in Table 1, there has been significant
research efforts into developing a biosensor to accurately
determine ATP concentration. One important aspect of
these studies is that none measure ATP directly, but
measure the oxidation of related compounds which are
related to ATP concentration such as hydrogen peroxide
[133]. The reason for this is that ATP is electrochem-
ically active at ~ 1 V which is an unsafe level of voltage
to be continuously applied [134]. Also, it can be seen
that these sensors react relatively slowly, with none of
the sensor designs producing a result in less than 10s.
This means that any control system connected to these
sensors would have a significant delay in the received
readings. The short active lifetime of the sensors is an
issue, due to the use of enzymes associated with the
detection mechanism. As was noted in the study by
Kueng A, Kranz C and Mizaikoff B [133], a response
time of under 100 ms would be ideal for measuring and
quantifying ATP at the cellular level. A key advantage of
this approach is that highly skilled personnel and sophis-
ticated computing resources are not required to inter-
pret the results as in chemiluminescence. This makes
amperometric biosensing a more viable proposition than
chemiluminescence as the sensing component in a
closed-loop control system.
The responses of an amperometric biosensor to ATP
concentration can be seen in Fig. 2. As can be observed
from the presented results, the sensor takes a number of
seconds to stabilize after the addition of ATP [135]. This
makes the method unsuitable for tracking highly dynamic
changes in ATP concentration. In situations where amper-
ometric sensing is unsuitable, or unable to gather the
results required, other related electrochemical techniques
are available. One such technique is cyclic voltammetry.
Cyclic voltammetry is an electrochemical technique where
the potential is increased and decreased in a repeated
manner, allowing for identification and measurement of
the analyte from its electrochemical oxidation/reduction at
known potentials [136–138]. A subtype of cyclic voltamm-
etry called Fast Scan Cyclic Voltammetry (FSCV) is of
particular interest when examining ATP concentrations as
it allows for readings to be taken in the millisecond range
[139]. FSCV varies the voltage potential at a high speed,
often at more than 1 kV/s with a cycle speed over 10 kHz
in order to gather highly transient readings from the ana-
lyte [137, 140]. An additional advantage of this high speed
changing of potential is that ATP can be directly measured,
as the electrodes do not maintain a high potential for an
extended period of time. FSCV is a well-established
electrochemical assaying technique, and has been used on
in-vivo brain tissue to gather sub-second readings of both
dopamine and adenosine [137, 141–143].
Recently a number of studies have investigated the
potential of FSCV to measure ATP concentration in-
vivo [144, 145]. This technique has several advantages
over the more established amperometric biosensors. It is
designed to take high speed measurements in the milli-
second range, and the electrodes used do not require
enzyme coatings and can thus be significantly smaller
(on the order of 7 μm diameter by 50 to 100 μm long)
[137, 142]. Smaller electrodes are preferred as they cause
less damage when being implanted into brain tissue
[146]. A number of research studies have identified these
advantages, and investigated FSCV for use as the sensor
portion in a closed-loop control system. de Araujo CE,
Abatti PJ, Da Cunha C, et al. [147], Chang S-Y, Kimble
CJ, Kim I, et al. [148], and Bozorgzadeh B, Schuweiler
DR, Bobak MJ, et al. [149] all describe closed-loop
control systems which use FSCV as the sensing element.
However, in all of these cases the sensing target is dopa-
mine release. If these techniques were instead modified
to detect and sense abnormalities in extracellular ATP, it
could open up treatment options beyond those which
are currently possible.
Table 1 Comparison of amperometric biosensors for measuring ATP concentration








Microelectrode Biosensor for Real-Time Measurement of
ATP in Biological Tissue [153]
Glycerol kinase and glycerol-3-
phosphate oxidase
H2O2 250 10s 25
ATP microelectrode biosensor for stable long-term in vitro
monitoring from gastrointestinal tissue [199]
Glucose oxidase and hexokinase H2O2 45.8 40–50s 50
Developmental aspects of amperometric ATP biosensors




Various 290 50–200 s 25
Co-immobilization of glucose oxidase and hexokinase on
silicate hybrid sol–gel membrane for glucose and ATP
detections [201]
Glucose oxidase and hexokinase
modified with silica hybrid sol-gel film
H2O2 10.8 15 s 3 × 10
3
Poly(benzoxazine) as immobilization matrix or miniaturized
ATP and glucose biosensors [202]
Glucose oxidase and hexokinase with
entrapment from a poly(benzoxazine)
derivative
H2O2 48.5 – 25
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Signal manipulator
The second part of the generic model depicted in Fig. 1 is
the signal manipulator element. This component receives
the output of the sensor and transforms it into a signal
which can be read by the control system. There are
multiple methods which chemiluminescent sensors use to
transform luminescence into useful signals depending on
the type of sensor being used. Traditionally, chemilumines-
cent assays are performed using an imaging chamber, super
cooled CCD camera (for noise reduction) and a display,
when used for manual interpretation, or image based signal
processors for automatic analysis [126, 150]. Unfortunately,
this means that this technique requires significant comput-
ing resources in order to convert the signal into one
decipherable by the control system, additionally the equip-
ment required is large, and resistant to miniaturization.
Highly sensitive chemiluminescent ATP sensors have
been developed by Iinuma M, Ushio Y, Kuroda A, et al.
[124] which immobilize luciferase molecules at the end
of an optic fiber to increase the spatial resolution and
increase the portability of the sensing element. However,
even this type of sensor requires sophisticated equip-
ment (photon detectors), resistant to miniaturization, in
order to convert the results to a format utilizable by a
control system [124, 151].
In comparison to the complexity of the chemilumines-
cent techniques, amperometric biosensors and FSCV based
sensors have relatively simple output signals for a control
system to read as the output is an analogue electronic
current which can be input to a control system through a
transimpedance amplifier and an Analogue to Digital
Converter (ADC) [129]. However, as the pertinent signals
are frequently in the nano-ampere range, signal manipula-
tion is required in order to produce a measurable signal.
This is normally achieved through amplification circuitry
which aims to increase the signal amplitude without adding
a significant amount of noise to the measurement [152].
This conversion and manipulation is usually performed by
commercially available data acquisition modules attached
to a computer [153–156]. However, a number of recent
investigators have developed their own discrete circuitry to
perform this task for size reduction and energy efficiency in
order to connect to a custom microcontroller based control
system and ultimately create an implantable system.
Controller
Once the signal from the sensors has been converted
into an appropriate format, the controller utilizes the
state of the system, and calculates what action (if any) is
appropriate to take. The lack of research on the topic of
closed-loop control systems sensing mitochondrial func-
tion was notable, and to the best of our knowledge, this
idea has so far not been considered in the existing litera-
ture. Several studies have, however, investigated the
possibility of amperometric biosensing and FSCV based
control systems for neurological conditions, using tar-
gets other than mitochondrial function.
de Araujo CE, Abatti PJ, Da Cunha C, et al. [147]
described a FSCV based system which allows for control
over dopamine concentration in-vitro. This system uses
a number of Arduino-based prototyping boards as the
hardware for the FSCV signal production and measurement
acquisition while using LabView (National Instruments) on
a host-computer for the controller. The effector used in this
study was a syringe pump which increased the amount of
dopamine in the system. The control algorithm used in this
system is not explicitly stated, however, the authors do
mention that the control is able to control the analyte
concentration to within +/− 0.8 μmol/L range with an oscil-
lation period of approximately 80s, indicating the system
used is likely some form of PID control [147]. The key
disadvantage of this system is that it requires a host-
computer to operate, and the control is operated through
the Lab-View software which severely limits the potential
for use of this system in-vivo.
Fig. 2 Response of an amperometric glycerol kinase and glycerol-3-phosphate oxidase biosensor to different concentrations of ATP in solution.
The linear relationship between output current and ATP concentration can be clearly observed (Adapted from: Palygin O, Levchenko V, Ilatovskaya
DV, et al. [135])
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Other researchers have developed systems which avoid
these issues, one such system is the “Neurochemostat”
developed by Bozorgzadeh B, Schuweiler DR, Bobak MJ,
et al. [149]. This system is a single CMOS chip design,
utilizing FSCV as the sensing element, and deep brain
stimulation (DBS) as the effector. This device is highly
suitable for in-vivo use, and the results of initial in-vivo
testing were included as part of the study. The control
scheme used was termed “on-off keying”, where the
effector was activated to an “On” state when the sensor
detected a value above a “High” threshold value. The
stimulation was deactivated when the sensor reported a
value below a “Low” value [149], this is illustrated in
Fig. 3 (a).
This system is suited to long-term in-vivo operation
on freely moving subjects, as it is entirely self-contained
and thus, no external devices are required in order for
the control system to operate. However, the control
algorithm used is a relatively simple one, and there is a
great deal of room for further investigation into more
effective control schemes. A much more comprehensive
approach was that taken by the Mayo Clinic reported in
the work by Grahn PJ, Mallory GW, Khurram OU, et al.
[157] seen in Fig. 3 (b). A two-layer adaptive neural
network was used to develop a system model, and a pre-
dictive controller was employed to achieve control of
dopamine release within the brain of the subject. This
solution is highly suitable for use in-vivo, and the results
were verified through testing on a number of in-vivo
models. The disadvantage of this approach is that it is
computationally intensive and requires much more
sophisticated hardware than the device described by
Bozorgzadeh B, Schuweiler DR, Bobak MJ, et al. [149] in
order to be run in real-time.
Viewing the state of the current research in this area,
there is clearly a number of aspects which are ripe for
further investigation. There is a great deal of room
between the simplicity of the control approach taken by
Bozorgzadeh B, Schuweiler DR, Bobak MJ, et al. [149]
and the complexity of the approach taken by Grahn PJ,
Fig. 3 a Diagram showing the “on-off keying” control scheme used by Bozorgzadeh B, Schuweiler DR, Bobak MJ, et al. [149] as part of their control
system. Adapted from: Bozorgzadeh B, Schuweiler DR, Bobak MJ, et al. [149]. b Model of the real-time closed-loop system developed by researchers at
the Mayo Clinic in order to control dopamine response within the brain. Adapted from: Grahn PJ, Mallory GW, Khurram OU, et al. [157]
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Mallory GW, Khurram OU, et al. [157]. This review did
not find any publication investigating the efficacy of
control schemes for this application in either a quantita-
tive or qualitative fashion. This could reflect the lack of
a standardized, commercially available platform which
would allow researchers to develop and compare avail-
able methods of control.
Effector
The final part of the system described in the generic
model in Fig. 1 is the effector. The role of the effector in
this model is an output which alters the mitochondrial
function, within the environment being sensed. The
effector of this type of system can take many forms such
as deep brain stimulation, drug therapy, or even a cogni-
tive or sensory task or stimulus, however, only those that
can be operated by an electronic control system will be
considered here.
Deep brain stimulation
The first effector method to be considered is deep brain
stimulation (DBS) which has been used in neurological
control systems studies. The stimulation parameters of a
DBS system are highly customizable and can be altered
through an electronic control system. This treatment
has established effectiveness in a significant number of
PD cases [149, 157–160]. DBS is an invasive neuromo-
dulatory approach, where electrodes are implanted into
the brain, and electrical impulses are delivered to the
brain tissue in order to alter the neurological signaling
within the target area [6]. DBS has been used as an
intervention for PD since the late 1980s. DBS is cur-
rently used extensively, however, the exact mechanisms
behind its efficacy as a treatment are still not completely
understood [161, 162].
Following its success as a treatment in PD, DBS has also
been investigated as a potential treatment for Alzheimer’s
disease with some preliminary studies finding that in appro-
priate patients, DBS might delay cognitive decline, and
result in improved quality of life [163–165]. Treatment
resistant depression (unipolar and bipolar) has also
been identified as a potential target for DBS therapy,
with several studies finding significant improvement in
depressive symptoms from patients receiving the treat-
ment [166–168].
In addition to assisting with other aspects of the disor-
ders, several studies have shown that electrical stimulation
can also have a direct impact on mitochondrial function,
[169–171]. A study by Bekar L, Libionka W, Tian G-F, et
al. [172] found that the effectiveness of deep brain stimu-
lation could be closely linked to the release of extracellular
ATP. Their research indicated that the activation of the
Adenosine A1 receptor reduced both tremor and side ef-
fects commonly associated with DBS treatments. If a sys-
tem was designed which worked in concert with this
finding, the existing DBS treatments could be delivered
while minimizing side effects.
There are various elements in a typical DBS signal
which can be altered to induce different responses in the
brain including: frequency, amplitude, and pulse-on time
[173]. This means that any control system utilizing DBS
as the effector component has many potential output
waveforms, consequently the control systems available
for consideration can have significantly more complexity
than on-off keying. A number of closed-loop control
systems for neurological conditions have been described
in the literature which utilize DBS as the effector, including
those developed by Bozorgzadeh B, Schuweiler DR, Bobak
MJ, et al. [149] and Grahn PJ, Mallory GW, Khurram OU,
et al. [157]. The system described in Grahn PJ, Mallory
GW, Khurram OU, et al. [157] customizes the activation,
amplitude, pulse width, and frequency of the DBS signal
based on the output of the control algorithm. There are
several DBS devices presented in the literature which could
be adapted for use as an effector in an electronic control
system, some of these are presented in Table 2.
The DBS systems presented in Table 2 are all low-cost
research devices which would be highly suited for
Table 2 DBS devices described in the literature which could be integrated into a control system




A Low Power Micro Deep Brain Stimulation Device for Murine Preclinical
Research. [203]
13.6 × 10.8 mm Monophasic 1 Adjustable 12 days
An inexpensive, charge-balanced rodent deep brain stimulation device:
a step-by-step guide to its procurement and construction [204]
– Biphasic 2 Fixed 21 days
Wireless implantable micro-stimulation device for high frequency bilateral
deep brain stimulation in freely moving mice [174]
30 × 8 mm Biphasic 2 Fixed 10 h
A long-lasting wireless stimulator for small mammals [205] 15x8x4mm Monophasic 1 Adjustable 21 days
Continuous high-frequency stimulation in freely moving rats: Development
of an implantable microstimulation system [206]
38x20x13.5 mm Biphasic 2 Fixed 22 days
SaBer DBS: a fully programmable, rechargeable, bilateral, charge-balanced
preclinical microstimulator for long-term neural stimulation [178]
33x20x8mm Biphasic 2 Adjustable 10 days
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integration into an electronic control system. Almost all
of the devices investigated were extremely low power
and able to actively produce stimulation signals for mul-
tiple days. The device by de Haas R, Struikmans R, van
der Plasse G, et al. [174] had the shortest running time,
however, this device was entirely implantable and was
thus restricted in the size of batteries selected. A num-
ber of the devices were only able to produce a fixed
stimulation parameter without significantly altering the
components included on the circuit board. These de-
vices limit the output options available to an electric
control system through altering the amplitude, frequency
or pulse width of the supplied stimulation, those
devices which can adjust these parameters would be
more suited to use in an electronic control system.
A number of the devices examined include multiple
channels of stimulation. This is most likely due to the
number of studies investigating bilateral DBS which
requires a second stimulation channel to be running
simultaneously [175–177]. The only device which
allows for fully adjustable stimulation of multiple
channels simultaneously, is the SaBer DBS device
created by Ewing SG, Porr B, Riddell J, et al. [178].
From this review it is clear that there are devices avail-
able to provide the stimulation required as a DBS
effector in a neurological control system, unfortu-
nately, the literature did not identify any existing
systems utilizing mitochondrial function in concert
with DBS for potentially increasing the effectiveness of
treatment.
Pharmacotherapy
While DBS is one choice for an effector mechanism it not
the only potential candidate, other more traditional pharma-
ceutical treatment options are also potential solutions. As
we develop our understanding of the mechanisms of neuro-
modulation, we will also see a simultaneous rise in improved
technologies for closed loop pharmacotherapy. Closed-loop
pharmacology has shown significant benefits in treatments
of other disorders such as diabetes and AIDS as well as for
administering anesthesia [179–181]. These studies found
that administering drugs through closed-loop mechanism
could increase precision while attempting to maintain a
specific concentration of the drug, while at the same time
minimizing the amount of overshoot [180]. A comparative
mathematical study performed by Caetano MA and
Yoneyama T [181] into closed-loop vs open-loop systems of
drug treatment for AIDS found that drug delivery schemes
with a closed-loop component improved quality of the treat-
ment, in particular in regards to the quantity of the drugs
administered. However, they noted that as the sensor
component they were using required frequent and periodic
laboratory testing, the closed-loop scheme was inconvenient.
If a portable sensor which doesn’t require a laboratory to
gather results like those described in Section V were to be
used, the potential therapeutic benefits of a closed-loop
pharmacological system could be considerable.
A number of studies have found positive results in neuro-
logical disorders through pharmacological treatments which
target aspects of the mitochondrial respiratory chain [73,
182–186]. A recent study by Karuppagounder S, Madathil
S, Pandey M, et al. [184] found that by administering a ROS
scavenging flavonoid (quercetin) to rat models of PD, stim-
ulated mitochondrial function and addressed oxidative
damage, indicating potential as a neuroprotective treatment
for neurodegenerative disease. This result is corroborated
by a study conducted by Kaariainen TM, Piltonen M,
Ossola B, et al. [187] on the same flavonoid using a different
model of PD, however, this second study found that
controlling the amount of quercetin administered was of
paramount importance as the effects became damaging
as the dosage increased. Mitochondrial modulation
using nutraceuticals boosting biogenesis is also being
explored as a potential treatment for bipolar depression
and chronic fatigue syndrome [188]. To support this,
technologies must be developed to support safe, pre-
cise, and controlled drug delivery.
One solution which shows significant promise is elec-
tronically controlled drug infusion micropumps. These
micropumps allow for precise control of both the timing
and volume of drug delivery [189]. This technology, when
integrated with an electronic control system, allows for
the realization of dynamic, personalized drug treatment
regimens, which are unique to each individual. This maxi-
mizes therapeutic outcomes while minimizing side effects
and unnecessary treatments [190]. A number of potential
drug delivery micropumps are compared in Table 3.
As can be seen in Table 3, there has been a significant
body of research in this area in the past 20 years, with a
number of different pumping mechanisms found to be
effective. In addition, there are several commercially
available options, however, these are resistant to integra-
tion with a custom developed control system and thus
are not considered. The majority of the pumps examined
used a piezoelectric diaphragm based mechanism to
move the fluid from the inlet to the outlet, this is pos-
sibly due to the simplicity of this mechanism, offering
potential for miniaturization. However, these pumps typ-
ically require a high voltage to operate, as shown in
Table 3, where even the low voltage piezoelectric pump
produced by Cazorla P-H, Fuchs O, Cochet M, et al.
[191] still requires a voltage of 24 V in order to operate.
This is an issue because a typical microcontroller based
control system runs at less than 12 V, and often at as
little as 3 V DC. This is also an issue in the electrostatic
pumps which require up to 200 V AC to operate [192].
The advantage of the electrostatic pumps is their very
small size. Both pumps measure less than 49mm3 and
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are among the smallest controllable pumps found in the
literature [192, 193]. The advantage of micropumps over
other drug delivery solution is the possibility of inter-
facing them with replaceable reservoirs which allow for
long-term treatments to be carried out without replacing
the pump.
The pumps developed by Cobo A, Sheybani R, Tu H,
et al. [194] and Gensler H, Sheybani R, Li P-Y, et al.
[195] appear to be the most suitable for integration into
a control system. Both systems run on 3 V DC and have
undergone extended testing to verify their precision and
performance and would be suitable selections for control
by the system outlined in Section VII. Overall, there is a
gap of studies that investigate that potential for control-
lable infusion micropumps to deliver drug treatments
for individuals with neurological conditions.
Discussion
In this paper, we reviewed the literature in order to present
an overview of the link between mitochondrial dysfunction
and various neurological disorders. Subsequently a generic
model of a closed-loop control system for controlling
neurological conditions through detecting mitochondrial
dysfunction was presented, and the components of the sys-
tem were examined.
The fact that mitochondrial dysfunction is intrinsically
linked to a number of neurological and psychiatric disor-
ders was made clear through the literature, although we
note that care must be taken to avoid the “post hoc ergo
propter hoc” logical fallacy. Although the disorder and
mitochondrial dysfunction are associated, more research
is required to determine if mitochondrial function is
upstream or downstream, cause or consequence of a
disorder. However, in all the disorders reviewed, the
mitochondrial function had been identified as a target
for future interventions, and in cases where therapies
directly targeted mitochondrial dysfunction, neuropro-
tective outcomes were reported [49, 66, 72, 87]. This is a
new area of investigation for some of neurological and
psychiatric disorders, which could provide significant











A bidirectional silicon micropump [192] Electrostatic 7x7x2 850 0.31 2 200
A wireless implantable micropump for chronic drug infusion against
cancer [194]
Electrolysis 20x15x7.1 2.66 0.69 – 3
Design and test of a high-performance piezoelectric micropump for
drug delivery [207]
Piezoelectric – 3.5 × 103 27 3 50
An Electromagnetically-Actuated All-PDMS Valveless Micropump for
Drug Delivery [208]
Electromagnetic 20x12x3.5 319.6 0.95 36.9 × 10−
3
–
A self-priming, roller-free, miniature, peristaltic pump operable with a
single, reciprocating actuator [209]
Peristaltic 8x22x35 780 48 – 3




4.34 × 103 14.64 0.2 36
An Ultrasonically Powered Micropump for On-Demand In-Situ Drug
Delivery [211]
Piezoelectric 22x7x5 13.8 4 – –
Characteristic studies of the piezoelectrically actuated micropump with
check valve [212]
Piezoelectric 10x10x1 1.82 × 103 32 160 120
Design and simulation of a novel electrostatic peristaltic micromachined
pump for drug delivery applications [193]
Electrostatic 7x4x1 9.1 – 50 18.5




3.6 4 1 24
An Implantable MEMS Micropump System for Drug Delivery in Small
Animals [195]
Electrolysis – 34 1.31 – 3
Piezoelectric Micropump with Nanoliter Per Minute Flow for Drug
Delivery Systems [214]
Piezoelectric 12x6x0.5 4.98 × 10
−3
– 0.67 16
Design and simulation of an implantable medical drug delivery system
using microelectromechanical systems technology [215]
Peristaltic 70x35x1 – – – 100
A PMMA valveless micropump using electromagnetic actuation [216] Electromagnetic – 400 1.2 12 × 10−3 –
A low voltage silicon micro-pump based on piezoelectric thin films [191] Piezoelectric 30 ×
7.5 × 0.15
3.5 3.2 1 24
Study on a piezoelectric micropump for the controlled drug delivery
system [217]
Piezoelectric – 52 – 0.4 140
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therapeutic benefits and greatly improve the quality of
life of the great number of individuals with these
disorders.
This new line of enquiry could be enhanced through inte-
gration with other modern innovations in the biomedical
sciences, such as miniaturized closed-loop control systems.
The benefits of a closed-loop system assessing mitochon-
drial function of a patient are self-evident, the treatment a
patient is receiving can be altered directly based on the
sensed severity of the disorder. This could even be com-
pleted on a long-term basis such as the patient being
assessed monthly using a non-invasive technique to deter-
mine treatment requirements. However, in disorders such
as BPD with highly dynamic and symptomatic changes in
mitochondrial function, a rapid closed loop system could
prove particularly advantageous. In this case, a method of
constantly sensing rapid mitochondrial danger signals would
have significant potential as a fast responding treatment
method which could respond to current environmental
demands or to alter based on longer-term state measures of
capacity. This type of fast-responding system was investi-
gated further in the generic model presented in this paper.
This model describes a technological solution which is
capable of treating these disorders in a manner which inte-
grates feedback, in order to enhance the precision of the
treatment delivery. Closed-loop control systems can be
personalized to each user, to ensure that the treatment
provided is necessary and pertinent, these systems are de-
signed to effectively treat disorders while minimizing
wasted treatments [181]. The model provided in Section
IV describes the control system as a series of functional
components including: the sensor, signal manipulator,
controller, and effector. Splitting the model into functional
components allows for the discussion of a number of
potential options for each component separately.
The first component to be examined was the sensor. A
number of sensor technologies were examined including
chemiluminescence, amperometry, and fast-scan cyclic
voltammetry. By examining these three sensor technologies
it is clear that while there are a number of options for
determining extracellular ATP concentration and mito-
chondrial function in-vivo, each of these technologies have
distinct advantages and disadvantages. Chemiluminescence
is a highly effective sensor technique with a high degree of
accuracy, and sensitivity. However, it requires relatively
large, sophisticated supporting technology in order to inter-
pret the output from the sensors. In situations where this
technology is available and there is sufficient space, this
method can be highly effective, however, for a portable
long-term closed-loop system this technique is unsuitable.
The second technique reviewed was amperometric bio-
sensing. Amperometric biosensing is another highly
sensitive technique which avoids the drawbacks found
with chemiluminescence, due to the output of the
sensor being a comparatively simple electrical signal.
However, these sensors take an extended period of time
to complete a measurement, which makes them unsuit-
able for detecting highly transient phenomena and have
a finite life. FSCV is a potential solution to this issue as
this technique includes the advantages of amperometric
biosensing whilst also being able to take measurements
with millisecond resolution. In addition, FSCV uses
smaller electrodes and does not require bound biological
agents on the electrodes in order to take a measurement.
Unfortunately, there was no significant literature found
which utilized FSCV to sense mitochondrial danger sig-
nals, so this technique is as yet unverified. From this, it is
obvious that there is no existing ideal solution for deter-
mining real-time mitochondrial function in-vivo, and that
this would be a valuable area for future engineering
researchers to focus on.
The key advantage of the ATP target over existing
biomarkers for closed-loop therapies is the focus on
measuring underlying causes instead of symptoms. Exist-
ing systems utilizing kinematics as a sensing agent for
disorder are limited to treating the disorder once it
becomes symptomatic rather than much earlier, like in
the neural recording system described in Section IV
[196]. Another advantage is the selectivity which is avail-
able temporally, specially, and chemically, while main-
taining the ability to be miniaturized. This type of sensor
adds another technique to the neural-sensing toolkit. It
could be used in concert with other methods of in-brain
sensing, such as local field potentials, and gather infor-
mation about neural activity as well as ATP movements
within the extracellular space [197]. These techniques
allow for measurements to be taken at regions, networks
and pathways which do not produce local field poten-
tials, giving us a more holistic view of the changes in the
brain during disorder.
The review of the controller component was disadvan-
taged by the fact that the authors could not find any
mitochondrial function based closed-loop control system
in the literature. In light of this absence, a short review
was conducted on a number of similar systems using
FSCV techniques to control other neurotransmitters,
mainly dopamine. Even with these systems, there was
not an extensive amount of literature investigating con-
trol schemes. A simple on-off keying control scheme
was outlined in the research conducted by Bozorgzadeh
B, Schuweiler DR, Bobak MJ, et al. [149]. This type of
system is a basic threshold control system, where the
output is activated at a particular level and when the
measurand reaches a prescribed level the output is deac-
tivated. On the other end of the spectrum was the
advanced control scheme used in the Mayo Clinic device
described by Grahn PJ, Mallory GW, Khurram OU, et al.
[157]. This review did not uncover any published
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research on the efficacy of different control schemes for
control of neurological conditions using FSCV sensors.
This lack of research may be explained by the absence of
a standard closed-loop platform for testing these
schemes. The development of such a platform would be
of great benefit when attempting to determine the most
effective scheme for treating neurological conditions in
this manner.
The final functional component of the generic closed-
loop system is the effector. The aim of the effector is to
alter the condition of the system in a manner that is
adjustable by the controller. In this review, two effector
types were considered, DBS devices and pharmacother-
apy. There were a number of DBS devices which were
suitable for integration into a control system. Due to the
relative simplicity of these devices, a number of researchers
have developed highly suitable devices which are able to
provide DBS pulses in an adjustable and controllable
manner. All of the devices surveyed were capable of produ-
cing suitable stimulation pulses, and the differentiating
factors were other capabilities such as number of stimula-
tion channels, and form-factor. This reflects the mature
state of open-loop DBS devices as a whole; the DBS
technology is ready for use in closed-loop control systems
and a number of systems which use local-field potentials
have already demonstrated this fact [198].
The next effector mechanism investigated was micro-
pump systems for controlled delivery of drug therapies.
Micropump systems in particular were reviewed due to
the ability to be integrated into an electronic control
system like that described in Section IV. These systems
when integrated with an electronic control system and
replaceable reservoirs, allowing for dynamic, highly con-
trolled delivery of drug treatments over extended periods
of time. The review clearly showed that there are a large
number of suitable candidates for integration into a
closed-loop system for neurological conditions. Like the
open-loop DBS devices, this reflects the maturity of this
technology as an effector mechanism. There were a
number of different pumping mechanisms which had
been investigated but the electrolysis pumps appear to
be the most suitable, as they run on lower voltage levels
than other pumping technologies such as piezoelectric.
Unfortunately, the authors could not find any published
studies in the literature where a drug infusion delivery
system had been paired with a neurochemical sensor, for
treatment of neurological disorders, which is an area
with significant potential benefits. Type one diabetes is
an example of a disorder where such a system has been
optimized, although the pathophysiology vastly simpler.
Conclusion
Links between brain mitochondrial dysfunction and neuro-
logical and psychiatric disorders are becoming increasingly
apparent and represent a targetable neurobiological mech-
anism for closed loop neuromodulation technologies. A
lack of an easy to use, millisecond resolution, in-vivo assay-
ing method is a critical hurdle that must be overcome in
order to advance research and therapeutic opportunities in
this area. In order to address this issue, we have presented a
generic model of a closed-loop control system which uti-
lizes the link between disorders and mitochondrial dysfunc-
tion to provide therapeutic intervention, and outlined each
of the functional components of such a system. From this
investigation, it was clear that there is still a need to carry
out further research in this area before a control system
such as the one described in the generic model can be
developed. The field of low-power closed-loop medical
devices is rapidly expanding, and while there are still a
number of hurdles to overcome prior to their widespread
use, the therapeutic benefits mean that this will be an area
for research for a number of years to come.
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